Aluminum absorption and excretion following sucralfate therapy in chronic renal insufficiency

Abstract

purpose: To measure serum aluminum levels and urinary aluminum excretion in patients with chronic renal insufficiency (CRF) receiving therapeutic doses of sucralfate. patients: Six patients with CRF were enrolled in the study. Creatinine clearances ranged from 0.2 to 0.9 mL/second (mean ± SD 0.40 ± 025 mL/second). Seven subjects with normal renal function were also studied. methods: Each subject received sucralfate 1 g four times daily for 21 days. Serum and urine samples (serum only) were collected on baseline and on Days 2, (3), 8, 15, 22, (23, 24), 29, and 36. Samples were assayed by graphite furnace atomic absorption spectrophotometry. results: In CRF, serum aluminum levels (μmol/L) increased by Day 2 and remained elevated to Day 24. Urinary aluminum excretion (μmol/day) was elevated throughout the study. The elimination half-life of serum aluminum after therapeutic dosing of sucralfate was 13.1 ± 3.1 days. In subjects with normal renal function, baseline serum aluminum levels were similar to those in CRF (0.12 ± 0.12 versus 0.11 ± 0.12 μmol/L), but serum aluminum levels were higher at the end of the study in CRF (Day 22, 0.24 ± 0.17 versus 0.83 ± 0.48 μmol/L). conclusions: After therapeutic doses of sucralfate, significant elevations of serum aluminum levels occurred in CRF. Serum aluminum levels were higher in patients with CRF than in normal subjects. Long courses of sucralfate should be used with caution or avoided in CRF.